| BNTC |
Benitec Biopharma Inc. |
Common Stock, par value $0.0001 |
44% |
$249,200,088 |
+$30,000,153 |
17,761,945 |
+14% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
07 Nov 2025 |
|
Veradermics, Inc |
Common Stock, par value $0.00001 |
12% |
|
|
4,168,991 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
05 Feb 2026 |
| IFRX |
InflaRx N.V. |
Common Shares, nominal value (euro)0.12 per share |
12% |
$8,647,962 |
|
7,933,910 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
31 Dec 2025 |
| MOLN |
MOLECULAR PARTNERS AG |
Common Shares, CHF 0.10 nominal value per share |
11% |
$17,696,249 |
|
4,284,806 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
15 Jun 2021 |
| WHWK |
Aadi Bioscience, Inc. |
Common Stock, par value $0.0001 per share |
10% |
$7,280,365 |
|
4,727,510 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
04 Mar 2025 |
| DBVT |
DBV Technologies S.A. |
Ordinary shares, nominal value 0.10 euro per share |
9.9% |
$129,451,408 |
|
15,176,015 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
07 Apr 2025 |
| AVBP |
ArriVent BioPharma, Inc. |
Common Stock, $0.0001 Par Value per Share |
9.9% |
$75,183,720 |
|
3,412,788 |
|
Suvretta Capital Management, LLC |
30 Jun 2025 |
| KURA |
Kura Oncology, Inc. |
Common Stock, par value $0.0001 per share |
9.4% |
$49,222,110 |
+$15,381,900 |
7,561,000 |
+45% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
31 Mar 2025 |
| FULC |
Fulcrum Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
9.4% |
$18,495,988 |
+$6,069,154 |
5,067,394 |
+49% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
31 Mar 2025 |
| ZURA |
Zura Bio Limited |
Class A Ordinary Shares, $0.0001 par value |
8.6% |
$29,171,085 |
|
5,567,001 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
31 Dec 2025 |
| IMTX |
Immatics N.V. |
ordinary shares, nominal value (euro)0.01 per share |
8.3% |
$117,496,354 |
-$8,820,000 |
11,190,129 |
-7% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
31 Dec 2025 |
| CMPX |
Compass Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
8.2% |
$44,559,662 |
+$21,967,265 |
14,101,159 |
+97% |
Suvretta Capital Management, LLC |
13 Aug 2025 |
| BHVN |
Biohaven Ltd. |
Common Shares, no par value |
7.8% |
$116,139,519 |
|
10,286,937 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
31 Dec 2025 |
| AURA |
Aura Biosciences, Inc. |
Common Stock, par value $0.00001 per share |
7.6% |
$30,091,360 |
+$10,524,518 |
4,701,775 |
+54% |
Suvretta Capital Management, LLC |
30 Jun 2025 |
| PVLA |
Palvella Therapeutics, Inc. |
Common stock, $0.001 par value per share |
7.4% |
$51,556,256 |
+$6,766,571 |
822,400 |
+15% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
30 Sep 2025 |
| CAPR |
Capricor Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
6.6% |
$80,730,585 |
|
3,417,891 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
19 Feb 2026 |
| ETNB |
89bio, Inc. |
Common Stock, par value $0.001 per share |
5.6% |
$121,716,000 |
-$93,071,712 |
8,280,000 |
-43% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
30 Sep 2025 |
| GLUE |
Monte Rosa Therapeutics, Inc. |
Common stock, par value $0.0001 per share |
5.5% |
$17,539,200 |
|
3,360,000 |
|
SUVRETTA CAPITAL MANAGEMENT, LLC |
09 Apr 2025 |
| MRNS |
Marinus Pharmaceuticals, Inc. |
Common Stock, par value $0.001 per share |
5.5% |
$1,662,437 |
+$504,541 |
3,022,612 |
+44% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
07 Feb 2025 |
| ABEO |
Abeona Therapeutics Inc. |
Common Stock, $0.01 par value |
5.2% |
$15,627,840 |
|
2,676,000 |
|
Suvretta Capital Management, LLC |
30 Jun 2025 |
| ERAS |
Erasca, Inc. |
Common Stock, $0.0001 par value per share |
5.1% |
$20,592,846 |
+$3,105,540 |
14,502,004 |
+18% |
Suvretta Capital Management, LLC |
30 Jun 2025 |
| PEPG |
PepGen Inc. |
Common Stock, par value $0.0001 per share |
0.9% |
$354,000 |
-$1,605,900 |
300,000 |
-82% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
30 Jun 2025 |
| STRO |
Sutro Biopharma, Inc. |
Common Stock, $0.001 par value |
0% |
$0 |
-$75,099,106 |
0 |
-100% |
SUVRETTA CAPITAL MANAGEMENT, LLC |
31 Dec 2025 |